Karen L. Smith Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Karen L. Smith.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Karen L. Smith. Karen L. Smith is Director in ANTARES PHARMA, INC. ($ATRS) and Director in SANGAMO THERAPEUTICS, INC ($SGMO) and EVP, R&D and CMO in Jazz Pharmaceuticals plc ($JAZZ) and Global Head of R&D and CMO in Jazz Pharmaceuticals plc ($JAZZ) and Director in ACCELERON PHARMA INC ($XLRN) and Director in Sucampo Pharmaceuticals, Inc. ($SCMP) and EVP, Chief Medical Officer in Emergent BioSolutions Inc. ($EBS).
Latest Insider Trading Transactions of Karen L. Smith
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, XLRN, ATRS, EBS, JAZZ, SGMO, SCMP
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 4,085 | |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 3,750 | |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 10,000 | |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 141.15 | 641 | 90,477 | 1,622 | 2.3 K to 1.6 K (-28.33 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 140.13 | 11,223 | 1,572,679 | 2,263 | 13.5 K to 2.3 K (-83.22 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
Apr 05 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 52.99 | 2,050 | 108,630 | 6,135 | |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 41.64 | 1,875 | 78,075 | 5,625 | |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | M | 35.34 | 5,000 | 176,700 | 15,000 | |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 137.92 | 941 | 129,783 | 4,561 | 5.5 K to 4.6 K (-17.10 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.92 | 3,796 | 519,748 | 5,502 | 9.3 K to 5.5 K (-40.83 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 136.22 | 2,987 | 406,889 | 9,298 | 12.3 K to 9.3 K (-24.31 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Sell | S | 134.54 | 1,201 | 161,583 | 12,285 | 13.5 K to 12.3 K (-8.91 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 52.99 | 2,050 | 108,630 | 13,486 | 11.4 K to 13.5 K (+17.93 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 41.64 | 1,875 | 78,075 | 11,436 | 9.6 K to 11.4 K (+19.61 %) |
Apr 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Buy | M | 35.34 | 5,000 | 176,700 | 9,561 | 4.6 K to 9.6 K (+109.63 %) |
Mar 01 2021 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Option Exercise | A | 11.19 | 16,400 | 183,516 | 16,400 | |
Mar 01 2021 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Grant | A | 0.00 | 8,200 | 0 | 25,700 | 17.5 K to 25.7 K (+46.86 %) |
Feb 26 2021 | EBS | Emergent BioSoluti ... | Smith Karen L. | EVP, Chief Medical ... | Option Exercise | A | 93.49 | 11,765 | 1,099,910 | 11,765 | |
Feb 26 2021 | EBS | Emergent BioSoluti ... | Smith Karen L. | EVP, Chief Medical ... | Grant | A | 0.00 | 2,941 | 0 | 12,193 | 9.3 K to 12.2 K (+31.79 %) |
Feb 26 2021 | EBS | Emergent BioSoluti ... | Smith Karen L. | EVP, Chief Medical ... | Grant | A | 0.00 | 2,942 | 0 | 9,252 | 6.3 K to 9.3 K (+46.62 %) |
Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,622 | 0 | 4,561 | 2.9 K to 4.6 K (+55.19 %) |
Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
May 20 2020 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Option Exercise | A | 10.46 | 15,000 | 156,900 | 15,000 | |
May 20 2020 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Grant | A | 0.00 | 2,500 | 0 | 10,000 | 7.5 K to 10 K (+33.33 %) |
Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 52.99 | 8,185 | 433,723 | 8,185 | |
Jan 24 2020 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,377 | 0 | 2,939 | 1.6 K to 2.9 K (+88.16 %) |
Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Grant | A | 2.92 | 23,973 | 70,001 | 23,973 | 0 to 24 K |
Jun 12 2019 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Option Exercise | A | 9.38 | 15,000 | 140,700 | 15,000 | |
Jun 12 2019 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Grant | A | 0.00 | 2,500 | 0 | 7,500 | 5 K to 7.5 K (+50.00 %) |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 41.64 | 7,500 | 312,300 | 7,500 | |
Jan 29 2019 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,250 | 0 | 1,562 | 312 to 1.6 K (+400.64 %) |
Jun 28 2018 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Option Exercise | A | 15.65 | 30,000 | 469,500 | 30,000 | |
Jun 28 2018 | SGMO | SANGAMO THERAPEUTI ... | Smith Karen L. | Director | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
Mar 07 2018 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Payment of Exercise | F | 143.39 | 648 | 92,917 | 28,474 | 29.1 K to 28.5 K (-2.23 %) |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 40.61 | 1,875 | 76,144 | 1,875 | |
Mar 05 2018 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 312 | 0 | 312 | 0 to 312 |
Mar 05 2018 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Option Exercise | A | 140.67 | 19,290 | 2,713,524 | 19,290 | |
Mar 05 2018 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Option Exercise | A | 140.67 | 710 | 99,876 | 710 | |
Mar 05 2018 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Grant | A | 0.00 | 8,000 | 0 | 29,122 | 21.1 K to 29.1 K (+37.88 %) |
Feb 13 2018 | SCMP | Sucampo Pharmaceut ... | Smith Karen L. | Director | Option Exercise | D | 10.95 | 30,000 | 328,500 | 0 | |
Nov 15 2017 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 35.34 | 20,000 | 706,800 | 20,000 | |
May 12 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Option Exercise | A | 155.18 | 2,500 | 387,950 | 2,500 | |
May 12 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Grant | A | 0.00 | 1,000 | 0 | 21,527 | 20.5 K to 21.5 K (+4.87 %) |
May 12 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | EVP, R&D and CMO | Payment of Exercise | F | 155.18 | 641 | 99,470 | 20,527 | 21.2 K to 20.5 K (-3.03 %) |
Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 136.18 | 17,848 | 2,430,541 | 17,848 | |
Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 136.18 | 902 | 122,834 | 902 | |
Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Grant | A | 0.00 | 7,500 | 0 | 21,168 | 13.7 K to 21.2 K (+54.87 %) |
Aug 12 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Buy | P | 137.26 | 1 | 137 | 14,182 | 14.2 K to 14.2 K (+0.01 %) |
Aug 12 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Buy | P | 137.10 | 607 | 83,218 | 14,181 | 13.6 K to 14.2 K (+4.47 %) |
Jul 13 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Buy | P | 143.63 | 580 | 83,305 | 13,574 | 13 K to 13.6 K (+4.46 %) |
Jun 15 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Buy | P | 149.61 | 557 | 83,335 | 12,994 | 12.4 K to 13 K (+4.48 %) |
May 12 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Payment of Exercise | F | 148.76 | 641 | 95,355 | 12,399 | 13 K to 12.4 K (-4.92 %) |
Feb 29 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 123.36 | 14,375 | 1,773,300 | 14,375 | |
Feb 29 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 123.36 | 625 | 77,100 | 625 | |
Feb 29 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Grant | A | 0.00 | 6,000 | 0 | 13,143 | 7.1 K to 13.1 K (+84.00 %) |
Apr 15 2016 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Payment of Exercise | F | 147.34 | 103 | 15,176 | 13,040 | 13.1 K to 13 K (-0.78 %) |
May 13 2015 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 176.51 | 15,516 | 2,738,729 | 15,516 | |
May 13 2015 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 176.51 | 2,264 | 399,619 | 2,264 | |
May 13 2015 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Grant | A | 0.00 | 275 | 0 | 7,105 | 6.8 K to 7.1 K (+4.03 %) |
May 13 2015 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Grant | A | 0.00 | 6,830 | 0 | 6,830 | 0 to 6.8 K |
Page: 1